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Coronary artery disease (CAD) is a disease of major concern worldwide. It is the main 
cause of mortality in many societies and improving the understanding about the CAD 
mechanism, progression and treatment, is necessary. Recent discovery of genetic factors 
underlying CAD has improved our knowledge of the disease in support of well-known 
traditional risk factors. Genotype-environment interaction is known as the main risk 
factor. Loci on many different chromosomes have been identified as a risk factors that 
increase CAD susceptibility. Here we performed a comprehensive literature review 
pinpointing hotspot loci involved in CAD pathogenicity. The 9p21.3 locus is the most 
common region associated with CAD and its specific structure and function have been 
remarkable in many studies. Moreover, the variations in the 9p21.3 locus have been 
implicated in CAD patients in different populations around the world. According to 
conclusions from this the 9p21.3 locus can be the first point of focus in etiology 




Genome Wide Association 
Study 
© 2019. International Journal 
of Cardiovascular Practice. 
INTRODUCTION
Cardiovascular diseases (CVD) involve the heart and 
blood vessels. Coronary heart disease (CHD) is one of 
a subset of CVD and a consequence of coronary artery 
disease (CAD) [1]. CAD is due to plaque aggregation in 
coronary arteries that leads to decreased blood supply to 
the heart muscle. This can lead to a wide spectrum of 
clinical manifestations ranging from asymptomatic to 
disease symptoms such as angina, silent myocardial 
infarction (MI), acute MI, and/or sudden death. It is a 
complex multifactorial disease to which genetic and 
environmental factors contribute. According to World 
Health Organization (WHO) reports, ischemic heart 
disease and stroke have been the most common causes 
of mortality in the last 15 years [2], and CHD as an 
ischemic heart disease is a global problem for all 
communities. It seems that national health control 
decisions are critical for CAD prevention in all 
populations [3]. Family history as a traditional factor 
that is independent from other risk factors can be useful 
in prediction of common diseases, e.g., CAD 
susceptibility in family members [4]. New technologies 
in recent years have improved the diagnosis of genetic 
differences between individuals in interacting with 
environment factors, such as the increased level of 
fibrinogen, homocysteine, C-reactive protein, low 
density lipoproteins (LDL), very low density 
lipoproteins (VLDL), cholesterol, triglyceride, systolic 
blood pressure, diastolic blood pressure, body mass 
index (BMI), lipoprotein A, decreased levels of high 
density lipoprotein (HDL), type 2 diabetes (T2D), 
some vitamin deficiencies, cofactor Q10, and other 
factors that increase over time [5, 6]. 
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Genetic Factors in Cad Causality 
According to twin and pedigree studies, genetic factors 
account for about 45% of the variation in CAD [7]. 
Swedish and Danish twin registry studies showed that 
genetic factors are important contributory causes of 
death of CHD patients, with the same frequency in 
males and females [8, 9]. Therefore, genetic-
environment interactions have been known as the main 
risk factor. Linkage studies also helped to identify 
inherited genes in large families with affected and 
unaffected individuals in different generations [10]. A 
monogenic forms of CAD were observed in a few cases 
of this disease and familial linkage studies established 
they were due to mutations in genes involved in known 
pathways of CAD such as lipid metabolism. Some of 
these cases are associated with increased LDL level, such 
as mutation in genes LDL receptor, ApoB-100, ARH and 
PCSK9 [11]. Low-density lipoprotein (LDL) consists of 
cholesteryl ester as the molecular which coated by 
phospholipid and Apolipoprotein B-100. About 600 
mutations in the LDL receptor gene leading to increased 
level of plasma LDL have been related to familial 
hypercholesterolemia. Mutations in the ApoB-100 and 
ARH genes are responsible for reduced LDL uptake 
from plasma and elevated LDL levels, leading to familial 
ligand-defective Apo lipoprotein B-100 and autosomal 
recessive hypercholesterolemia, respectively [12]. The 
PCSK9 gene encodes a protease enzyme that is involved 
in degradation of LDL receptor, and affects LDL 
metabolism leading to CHD. Overexpression of the 
PCSK9 gene, or gain of function mutations, is related to 
hypercholesterolemia versus loss-of-function 
mutations, or inactivation of the enzyme, is related to 
hypocholesterolemia which has a protective effect on 
CHD. Therefore, we can target the PCSK9 gene as a way 
of treatment of CHD in the future [13]. 
Plasma HDL reduction as a risk factor for CAD is due to 
mutations in genes such as ApoA1, ABCA1, and LCAT 
that cause familial hypoalphalipoproteinemia, Tangier 
disease, and Norum disease, respectively. Reduction of 
HDL and increased risk of CAD are observed in these 
disorders [11]. CAD has also been associated with 
polymorphisms in genes such as ApoA1-75A, R219K in 
ApoA1 and ABCA1 [14, 15]. High level of plasma 
triglyceride as a risk factor for CAD is associated with 
mutations in genes such as LPL and ApoCII that lead to 
hyperlipoproteinemia type I and hyperlipoproteinemia 
type Ib, respectively [11]. Mutations in another group of 
genes without a direct effect on alteration of plasma lipid 
levels including MEF2A, LRP6, CYP27A1, 
ST6GALNAC5, ABCG5, and ABCG8 also increase the 
risk of CAD.  
Gene MEF2A encodes a transcription factor that is 
expressed in endothelial cells of coronary arteries. 
Deletion of 7 amino acids of exon 11 of this transcription 
factor is associated with CAD and MI [16]. In another 
study three missense mutations including N263S, 
P279L and G283D identified in MEF2A caused 
reductions in transcription factor activity and hence 
were associated with CAD [17].  
Mutations p.Val99Met and p.*337Qext*20 in the gene 
ST6GALNAC5 were associated with CAD in the Iranian 
population. The mutant alleles of ST6GALNAC5, 
which encodes the sialyltransferase 7e, causes increased 
activity of the enzyme [18, 19]. 
Iranloorahatloo et al. demonstrated that the mutation 
p.Arg225His in gene CYP27A1 is associated with CAD 
in the Iranian population. CYP27A1 encodes the 
enzyme sterol 27-hydroxylase that is involved in vitamin 
D metabolism and reverse transportation of cholesterol. 
The mutant enzyme likely affects the reverse 
transportation of cholesterol [20]. Gene LRP6 encodes 
LDL receptor-related protein 6 and a missense mutation 
named p.R611C in an Iranian ancestry is associated with 
CAD. The mutation is associated with high levels of 
LDL and TG but has no direct effect on HDL level [21]. 
Mutations in genes ABCG5 and ABCG8, which encode 
transporters that influence cholesterol absorption, are 
the most causes of sitosterolemia and involve hyper 
absorption of sterols and cholesterol, again leading to 
increased  risk of CAD [12]. 
Recent Approaches in Assessing Diseases 
Etiology 
The recent sequencing of the entire human genome by 
the Human Genome Project and linkage disequilibrium 
(LD) patterns revealed in the Hap Map project led to 
discovery of single nucleotide polymorphisms (SNP) 
using microarray technology approaches and to the 
ability to perform genome-wide association studies 
(GWAS) [10]. GWAS detects statistical associations 
between SNP as genome markers with the phenotype 
(disease) with no previous hypothesis [22, 23]. 
Candidate gene studies are another type of association 
analysis. This type of study has been used for complex 
diseases and is based on comparisons of selected loci or 
alleles identified in earlier studies [22]. Since candidate 
gene studies are based on previous hypotheses loci in 
unknown pathways of disease pathogenesis cannot be 
studied. Conflicting and difficult confirmation results 
are disadvantages of Candidate gene study [24], Whole-
genome sequencing (WGS) is a technology based on 
sequencing entire genomes and the method has focused 
mainly on simply inherited disorders and identification 
of rare variants with large effects [22]. Due to lack of 
distinction between causal and non-causal variants in 
the pathogenesis of the disease, this approach is useful 
for identification of mutations or genes that were 
confirmed in previous studies [25]. 
In addition to genomics studies, proteomics studies are 
helpful in identification of new genes associated with 
CAD [26]. You et al. compared the proteomes of 
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coronary arteries of CAD patients and control 
individuals. Two-dimensional electrophoresis and mass 
spectrometry showed elevated expression of light chain 
ferritin in CAD patients that was possibly associated 
with CAD by oxidation of lipid components of coronary 
artery plaques [27]. Recently designed commercial 
microarrays consisting of many common SNP 
distributed throughout the human genome have been 
used in different populations to locate genome markers 
associated with CAD. GWAS are based on allele 
frequencies and statistical differences among thousands 
of disease cases and control populations. The required 
level of statistical significance for confirmation of 
associated variants with disease in GWAS is set at P = 
5×10−8. Associated markers when identified should be 
confirmed in different ethnic populations around the 
world [28]. GWAS was first proposed in the mid-1990s 
and 2006 saw the beginning of data from such studies 
[10]. The first robustly associated locus with CAD was 
located at position 9p21.3 on the short arm of 
chromosome 9 three independent GWAS in 2007 [29-
31].  
Genetic Association Studies of CAD during the 
Last Decade 
1. Highlights for the Year 2007 
McPherson et al. reported a 58 kb region in locus 9p21 
that was associated with CHD in six Caucasian 
individuals and identified homozygous form of risk 
alleles increased CHD susceptibility about 35% [29]. 
Helgadottir et al. described a risk variant in 9p21.3 that 
was associated with MI. They concluded that the risk of 
MI in individuals homozygous for this allele was 1.64-
fold more than heterozygous carriers [30]. Another 
study, the Welcome Trust Case Control Consortium 
(WTCCC) reported a survey of common human 
diseases such as CAD in about 50 cohorts from different 
places of the United Kingdom, and nominated 9p21.3 as 
a strongest associated locus with CAD. Other loci were 
also implicated in this study and some of them were 
confirmed in further studies [31]. Samani et al, in 
another GWAS combining data from two significant 
studies of white European populations, WTCCC and a 
German MI family study, found that 9p21.3, 6p25.1 and 
2q36.3 were associated with CAD. Moreover, their 
combined analysis identified four potentially novel loci 
with high probabilities of association with CAD: 1p13.3, 
1q41, 10q11.21, and 15q22.33 [32]. 
2. Highlights for the Year 2009 
Seven loci, including 9p21.3, 6p25.1, 2q36.3, 1p13.3, 
1q41, 10q11.21, and 15q22.33, which discovered in 
2007 in a GWAS of nine European populations; 9p21.3 
was clearly associated with CAD, and there was also 
convincing evidence for associations of the SORT1 
(1p13.3), MIA3 (1q41) and CXCL12 (10q11.21) loci 
with CAD, but not 6p25.1, 2q36.3 and 15q22.33 [33]. 
Erdmann et al. in a three-stage GWA analysis of the 
German population confirmed two loci including 
9p21.3 and 1q41 and reported a novel MRAS (3q22.3) 
locus [34]. In another three-stage meta-analysis eight 
genes were associated with early onset of MI, six of them 
were reported previously and the novel loci were 
SLC5A3-MRPS6-KCNE2 (21q22.11) and PHACTR1 
(6p24.1). They also reported the WDR12 (2q33.1) 
locus [35], which was confirmed as a locus associated 
with CAD by Schunkert et al. in 2011 [36]. From a 
genome-wide haplotype association (GWHA) study 
Tregouet et al. discovered a cluster of genes, including 
SLC22A3-LPAL2-LPA (6q26-q27(, associated with 
CAD [37]. Gudbjartsson et al. demonstrated an 
association of gene SH2B3 (12q24) with MI in six 
different populations [38]. In a different study Soranzo 
et al. found that locus 12q24 was associated with 
increased platelet counts and an increased risk of CAD. 
They discovered a large haplotype block of about 1.6 
Mb in the 12q24 locus which is associated with CAD. 
This haplotype block included ten SNP, one of which 
was a missense mutation in gene SH2B3, seven were 
intronic polymorphisms in genes ATXN2, C12orf30, 
C12orf51 and PTPN11, and the remaining two were 
intragenic polymorphisms [39]. 
3. Highlights for the Years 2010/2011 
Schunkert et al. (2011) reported thirteen novel loci as 
risk factors for CAD in a meta-analysis of 14 GWAS. 
These loci were PPAP2B (1p32.2), ANKS1A (6p21.31), 
TCF21 (6q23.2), ZC3HC1 (7q32.2), ABO (9q34.2), 
CYP17A1-CNNM2-NT5C2 (10q24.32), ZNF259-
APOA5-APOA1 (11q23.3), COL4A1/A2 (13q34), 
HHIPL1 (14q32.2), ADAMTS7 (15q25.1), RAI1-
PEMT-RASD1 (17p11.20), SMG6 (17p13.3), and 
UBE2Z (17q21.32) [36]. In another study of European 
and South Asian cohorts, Mehta reported five novel loci 
associated with CAD, including LIPA (10q23), PDGFD 
(11q22), ADAMTS7-MORF4L1 (15q25), BCAP29 
(7q22), and KIAA1462 (10p11) [40]. Locus 10p11.23 
was also found by Erdmann et al. (2010) in a study of a 
German MI Family (GerMIFS) that finally detected a 
missense mutation in KIAA1462, a CAD related gene 
[41]. Four other novel genes in GWAS of European and 
South Asian populations included LIPA (10q23.31), 
IL5 (5q31.1), TRIB1 (8q24.13), and ABCG5/ABCG8 
(2p21) [42]. 
4. Highlights for the Year 2013 
Deloukas et al. identified thirteen novel loci associated 
with CAD in a large-scale analysis. They combined data 
from 14 GWAS (CARDIoGRAM Consortium) with 
data from 34 additional European and South Asian 
populations and validate the SNP in four independent 
populations. In addition to confirming many loci from 
previous studies they reported a number of new loci 
associated with CAD, including IL6R (1q21), APOB 
(2p24.1), VAMP5-VAMP8-GGCX (2p11.2), SLC22A4-
SLC22A5 (Chr5), ZEB2-AC074093.1 (Chr2), 
GUCY1A3 (4q31.1), KCNK5 (6p21), LPL (8p22), 
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PLG (6q26), FURIN-FES (15q26.1), FLT1 (13q12), 
EDNRA (Chr4) and HDAC9 (7p21), and AK097927 
(chr2) [43]. 
5. Highlights for the Year 2015 
Nikpay et al. reported ten novel loci associated with 
CAD, including REST-NOA1 (4q12), NOS3 (7q36), 
SWAP70 (11p15), SMAD3 (15q22), MFGE8-ABHD2 
(15q26), BCAS3 (17q23), PMAIP1-MC4R (18q21), 
POM121L9P-ADORA2A (22q11), KSR2 (12q24), and 
ZNF507-LOC400684 (19q13) [44] . 
6. Highlights for the Year 2017 
Webb et al. added six new loci associated with CAD, 
including KCNJ13-GIGYF2 (2q37), C2 (6p21), 
MRVI1-CTR9 (11p15), LRP1 (12q13), SCARB1 
(12q24), and CETP (16q13) [45]. Verweij et al. 
reported fifteen novel loci, among which there were 
genes involved in angiogenesis. These were: TDRKH 
(1q21.3), RHOA-AMT-TCTA (3p21.31), UMPS-
ITGB5 (3q21.2), SGEF (3q25.2), PRDM8-FGF5 
(4q21.21), MAD2L1 (4q27), ZNF827 (4q31.21), 
HDGFL1 (6p22.3), ARNTL (11p15.2), HOXC4 
(12q13.13), HNF1A (12q24.31), TMED10 (14q24.3), 
BCAR1 (16q23.1), CDH13 (16q23.3), and 
HNRNPUL1-TGFB1-B9D2 (19q13.2) [46]. In 
addition, there fifteen additional novel loci reported by 
Howson et al. identified several genes with various 
functions such as cell adhesion, leucocyte migration, 
coagulation, inflammation, VSMC differentiation, and 
atherosclerosis, these novel loci were ATP1B1 (chr1), 
DX59/CAMSAP2 (chr1), LMOD1 (chr1), TNS1 
(chr2), ARHGAP26 (chr5), PARP12 (chr7), PCNX3 
(chr11), SERPINH1 (chr11), C12orf43/HNF1A 
(chr12), SCARB1 (chr12), OAZ2-RBPMS2 (chr15), 
DHX38 (chr16), GOSR2 (chr17), PECAM1 (chr17), 
and PROCR (chr20) [47]. 
7. Highlights for the Year 2018 
van der Harst and Verweij (2018) upgraded our insight 
and knowledge of the genetic architecture of CAD by 
detection of sixty four new loci [48]. All reported loci 
and their variants are summarized in Table 1. 
Table 1. Recent Reports of CAD/MI-Associated loci 
No. Chromosomal location Gene Year Reference 
1 9p21.3 CDKN2/AB 2007 [29-31] 
2 1p13.3 SORT1 2007-2009 [33] 
3 1q41 MIA3 2007-2009  
4 10q11.21 CXCL12 2007-2009  
5 3q22.3 MRAS 2009 [34] 
6 21q22.11 SLC5A3-MRPS6-KCNE2 2009 [35] 
7 6p24.1 PHACTR1 2009  
8 2q33.1 WDR12 2009-2011  
9 6q26-q27 SLC22A3-LPAL2-LPA 2009 [37] 
10 12q24 SH2B3 2009 [38, 39] 
11 1p32.2 PPAP2B 2011 [36] 
12 6p21.31 ANKS1A 2011  
13 6q23.2 TCF21 2011  
14 7q32.2 ZC3HC1 2011  
15 9q34.2 ABO 2011  
16 10q24.32 CYP17A1-CNNM2-NT5C2 2011  
17 11q23.3 ZNF259-APOA5-APOA1 2011  
18 13q34 COL4A1/A2 2011  
19 14q32.2 HHIPL1 2011  
20 15q25.1 ADAMTS7 2011 [36, 40] 
21 17p11.2 RAI1-PEMT-RASD1 2011  
22 17p13.3 SMG6 2011  
23 17q21.32 UBE2Z 2011  
24 10q23 LIPA 2011 [40, 42] 
25 11q22 PDGFD 2011  
26 7q22 BCAP29 2011  
27 10p11.23 KIAA1462 2011/2010 [40, 41] 
28 5q31.1 IL5 2011 [42] 
29 8q24.13 TRIB1 2011  
30 2p21 ABCG5/ABCG8 2011  
31 1q21 IL6R 2013 [43] 
32 2p24.1 APOB 2013  
33 2p11.2 VAMP5-VAMP8-GGCX 2013  
34 Chr5 SLC22A4-SLC22A5 2013  
35 Chr2 ZEB2-AC074093.1 2013  
36 4q31.1 GUCY1A3 2013  
37 6p21 KCNK5 2013  
38 8p22 LPL 2013  
39 15q26.1 FURIN-FES 2013  
40 6q26 PLG 2013  
41 13q12 FLT1 2013  
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42 Chr4 EDNRA 2013  
43 7p21.1 HDAC9 2013  
44 4q12 REST-NOA1 2015 [44] 
45 7q36 NOS3 2015  
46 11p15 SWAP70 2015  
47 15q22 SMAD3 2015  
48 15q26 MFGE8-ABHD2 2015  
49 17q23 BCAS3 2015  
50 18q21 PMAIP1-MC4R 2015  
51 22q11 POM121L9P-ADORA2A 2015  
52 12q24 KSR2 2015  
53 19q13 ZNF507-LOC400684 2015  
54 2q37 KCNJ13-GIGYF2 2017 [45] 
55 6p21 C2 2017  
56 11p15 MRVI1-CTR9 2017  
57 12q13 LRP1 2017  
58 12q24 SCARB1 2017 [45, 47] 
59 16q13 CETP 2017  
60 1q21.3 TDRKH 2017 [46] 
61 3p21.31 RHOA-AMT-TCTA 2017  
62 3q21.2 UMPS-ITGB5 2017  
63 3q25.2 SGEF 2017  
64 4q21.21 PRDM8-FGF5 2017  
65 4q27 MAD2L1 2017  
66 4q31.21 ZNF827 2017  
67 6p22.3 HDGFL1 2017  
68 11p15.2 ARNTL 2017  
69 12q13.13 HOXC4 2017  
70 12q24.31 HNF1A 2017  
71 14q24.3 TMED10 2017  
72 16q23.1 BCAR1 2017  
73 16q23.3 CDH13 2017  
74 19q13.2 HNRNPUL1-TGFB1-B9D2 2017  
75 chr1 ATP1B1 2017 [47] 
76 chr1 DX59/CAMSAP2 2017  
77 chr1 LMOD1 2017  
78 chr2 TNS1 2017  
79 chr5 ARHGAP26 2017  
80 chr7 PARP12 2017  
81 chr11 PCNX3 2017  
82 chr11 SERPINH1 2017  
83 chr12 C12orf43/HNF1A 2017  
84 chr15 OAZ2-RBPMS2 2017  
85 chr16 DHX38 2017  
86 chr17 GOSR2 2017  
87 chr17 PECAM1 2017  
88 chr20 PROCR 2017  
89 1p36.33 MORN1 2018 [48] 
90 1p36.32 PRDM16 2018  
91 1p34.3 FHL3 2018  
92 1p13.2 NGF 2018  
93 1q32.2 HHAT 2018  
94 1q42.2 AGT 2018  
95 2p21 PRKCE 2018  
96 2q24.3 FIGN 2018  
97 2q32.1 CALCRL 2018  
98 2q37.3 COL6A3 2018  
99 3p21.31 ALS2CL 2018  
100 3p21.31 CDC25A 2018  
101 3q22.1 DNAJC13 2018  
102 3q22.3 STAG1 2018  
103 3q25.31 CCNL1 2018  
104 3q26.31 FNDC3B 2018  
105 4p16.3 HGFAC-RGS12 2018  
106 4q21.1 SHROOM3 2018  
107 4q21.22 HNRNPD 2018  
108 4q22.3 UNC5C 2018  
109 4q32.3 PALLD 2018  
110 5p15.31 SEMA5A 2018  
111 5q11.2 MAP3K1 2018  
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112 6p25.3 FOXC1 2018  
113 6p21.2 CDKN1A 2018  
114 6p21.1 VEGFA 2018  
115 6p11.2 PRIM2 2018  
116 6q14.1 FAM46A 2018  
117 6q22.32 CENPW 2018  
118 6q25.1 PLEKHG1 2018  
119 7p22.3 MAD1L1 2018  
120 7p22.1 DAGLB 2018  
121 7p21.3 TMEM106B 2018  
123 7p13 CCM2 2018  
124 7q31.2 CTTNBP2 2018  
125 8p22 NAT2 2018  
126 8p21.3 BMP1 2018  
127 8q23.1 ZFPM2 2018  
128 9q31.2 KLF4 2018  
129 9q33.2 DAB2IP 2018  
130 10p13 CDC123 2018  
131 10q23.1 TSPAN14 2018  
132 10q24.33 STN1 2018  
133 10q26.13 HTRA1 2018  
134 11p15.4 TRIM5-TRIM22 2018  
135 11p11.2 HSD17B12 2018  
136 11q22.1 ARHGAP42 2018  
137 12p13.31 C1S 2018  
138 12q22 NDUFA12 2018  
139 13q13.1 N4BP2L2-PDS5B 2018  
140 13q34 MCF2L 2018  
141 14q23.1 ARID4A 2018  
142 14q32.13 SERPINA2 2018  
143 15q26.2  2018  
144 16q23.3 PLCG2 2018  
145 17q11.2 CORO6-ANKRD13B 2018  
146 17q11.2 COPRS 2018  
147 17q21.2 DHX58-KAT2A 2018  
148 18q21.1 ACAA2 2018  
149 19p13.11 MAP1S-FCHO1 2018  
150 20q12 ZHX3 2018  
151 20q13.12 PCIF1-ZNF335 2018  
152 20q13.32 ZNF831 2018  
153 21q21.3 MAP3K7CL 2018  
CDKN2/AB, Cyclin Dependent Kinase Inhibitor 2/AB; SORT1, Sortilin 1; MIA3, MIA SH3 domain ER export factor 3; CXCL12, C-X-C motif chemokine ligand 
12; MRAS, muscle RAS oncogene homolog; SLC5A3, solute carrier family 5 member 3; MRPS6, mitochondrial ribosomal protein S6; KCNE2, potassium voltage-
gated channel subfamily E regulatory subunit 2; PHACTR1, phosphatase and actin regulator 1; WDR12, WD repeat domain 12; SLC22A3, solute carrier family 22 
member 3; LPAL2, lipoprotein(a) like 2, pseudogene; LPA, lipoprotein(a); SH2B3, SH2B adaptor protein 3; PPAP2B, phospholipid phosphatase 3; ANKS1A, 
ankyrin repeat and sterile alpha motif domain containing 1A; TCF21, transcription factor 21; ZC3HC1, zinc finger C3HC-type containing 1; ABO, ABO, alpha 1-
3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase; CYP17A1, cytochrome P450 family 17 subfamily A member 1; CNNM2, cyclin and 
CBS domain divalent metal cation transport mediator 2; NT5C2, 5'-nucleotidase, cytosolic II; ZNF259, zinc finger protein 259; APOA5, apolipoprotein A5; 
APOA1, apolipoprotein A1; COL4A1, collagen type IV alpha 1 chain; COL4A2, collagen type IV alpha 2 chain; HHIPL1, HHIP like 1; ADAMTS7, ADAM 
metallopeptidase with thrombospondin type 1 motif 7; RAI1, retinoic acid induced 1; PEMT, phosphatidylethanolamine N-methyltransferase; RASD1, ras related 
dexamethasone induced 1; SMG6, SMG6, nonsense mediated mRNA decay factor; UBE2Z, ubiquitin conjugating enzyme E2 Z; LIPA, lipase A, lysosomal acid 
type; PDGFD, platelet derived growth factor D; MORF4L1, mortality factor 4 like 1; BCAP29, B cell receptor associated protein 29; KIAA1462, JCAD junctional 
cadherin 5 associated; IL5, interleukin 5; TRIB1, tribbles pseudokinase 1; ABCG5, ATP binding cassette subfamily G member 5; ABCG8, ATP binding cassette 
subfamily G member 8; IL6R, interleukin 6 receptor; APOB, apolipoprotein B; VAMP5, vesicle associated membrane protein 5 VAMP8, vesicle associated 
membrane protein 8; GGCX, gamma-glutamyl carboxylase; SLC22A4, solute carrier family 22 member 4; SLC22A5, solute carrier family 22 member 5; ZEB2, 
zinc finger E-box binding homeobox 2.; GUCY1A3, guanylate cyclase 1 soluble subunit alpha 1; KCNK5, potassium two pore domain channel subfamily K 
member 5; LPL, lipoprotein lipase; FURIN, furin, paired basic amino acid cleaving enzyme; FES, FES proto-oncogene, tyrosine kinase; PLG, plasminogen;  FLT1, 
fms related tyrosine kinase 1; EDNRA, endothelin receptor type A; HDAC9, histone deacetylase 9; REST, RE1 silencing transcription factor; NOA1, nitric oxide 
associated 1; NOS3, nitric oxide synthase 3; SWAP70, switching B cell complex subunit SWAP70; SMAD3, SMAD family member 3; MFGE8, milk fat globule-
EGF factor 8 protein; ABHD2, abhydrolase domain containing 2; BCAS3, BCAS3, microtubule associated cell migration factor; PMAIP1, phorbol-12-myristate-
13-acetate-induced protein 1; MC4R, melanocortin 4 receptor; POM121L9P, POM121 transmembrane nucleoporin like 9, pseudogene; ADORA2A, adenosine 
A2a receptor; KSR2, kinase suppressor of ras 2; ZNF507, zinc finger protein 507; KCNJ13, potassium voltage-gated channel subfamily J member 13; GIGYF2, 
GRB10 interacting GYF protein 2; C2, complement C2; MRVI1, murine retrovirus integration site 1 homolog; CTR9, CTR9 homolog, Paf1/RNA polymerase II 
complex component; LRP1, LDL receptor related protein 1; CETP, cholesteryl ester transfer protein; TDRKH, tudor and KH domain containing; RHOA, ras 
homolog family member A; AMT, aminomethyltransferase; TCTA, T cell leukemia translocation altered; UMPS, uridine monophosphate synthetase; ITGB5, 
integrin subunit beta 5; SGEF, Rho guanine nucleotide exchange factor (GEF) 26; PRDM8, PR/SET domain 8; FGF5, fibroblast growth factor 5; MAD2L1, mitotic 
arrest deficient 2 like 1; ZNF827, zinc finger protein 827; HDGFL1, HDGF like 1; ARNTL, aryl hydrocarbon receptor nuclear translocator like; HOXC4, homeobox 
C4; HNF1A, HNF1 homeobox A; TMED10, transmembrane p24 trafficking protein 10; BCAR1, breast cancer anti-estrogen resistance 1; CDH13, cadherin 13; 
HNRNPUL1, heterogeneous nuclear ribonucleoprotein U like 1; TGFB1, transforming growth factor beta 1; B9D2, B9 domain containing 2; ATP1B1, ATPase 
Na+/K+ transporting subunit beta 1; DX59/CAMSAP2, calmodulin regulated spectrin associated protein family member 2; LMOD1, leiomodin 1; TNS1, tensin 1; 
ARHGAP26, Rho GTPase activating protein 26; PARP12, poly(ADP-ribose) polymerase family member 12; PCNX3, pecanex 3; SERPINH1, serpin family H 
member 1; C12orf43, chromosome 12 open reading frame 43; HNF1A, HNF1 homeobox A; SCARB1, scavenger receptor class B member 1; OAZ2, ornithine 
decarboxylase antizyme 2; RBPMS2, RNA binding protein, mRNA processing factor 2; DHX38, DEAH-box helicase 38; GOSR2, golgi SNAP receptor complex 
member 2; PECAM1, platelet and endothelial cell adhesion molecule 1; PROCR, protein C receptor; MORN1, MORN repeat containing 1; PRDM16, PR/SET 
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domain 16; FHL3, four and a half LIM domains 3; NGF, nerve growth factor; HHAT, hedgehog acyltransferase; AGT, angiotensinogen; PRKCE, protein kinase 
C epsilon; FIGN, fidgetin, microtubule severing factor; CALCRL, calcitonin receptor like receptor; COL6A3, collagen type VI alpha 3 chain; ALS2CL, ALS2 C-
terminal like; CDC25A, cell division cycle 25A; DNAJC13, DnaJ heat shock protein family (Hsp40) member C13; STAG1, stromal antigen 1; CCNL1, cyclin L1; 
FNDC3B, fibronectin type III domain containing 3B; RGS12, regulator of G protein signaling 12; HGFAC, HGF activator; SHROOM3, shroom family member 
3; HNRNPD, heterogeneous nuclear ribonucleoprotein D; UNC5C, unc-5 netrin receptor C; PALLD, palladin, cytoskeletal associated protein; SEMA5A, 
semaphorin 5A; MAP3K1, mitogen-activated protein kinase kinase kinase 1; FOXC1, forkhead box C1; CDKN1A, cyclin dependent kinase inhibitor 1A; VEGFA, 
vascular endothelial growth factor A; PRIM2, DNA primase subunit 2; FAM46A, family with sequence similarity 46 member A; CENPW, centromere protein W; 
PLEKHG1, pleckstrin homology and RhoGEF domain containing G1; MAD1L1, mitotic arrest deficient 1 like 1; DAGLB, diacylglycerol lipase beta; TMEM106B, 
transmembrane protein 106B; CCM2, CCM2 scaffold protein; CTTNBP2, cortactin binding protein 2; NAT2, N-acetyltransferase 2; BMP1, bone morphogenetic 
protein 1; ZFPM2, zinc finger protein, FOG family member 2; KLF4, Kruppel like factor 4; DAB2IP, DAB2 interacting protein; CDC123, cell division cycle 123; 
TSPAN14, tetraspanin 14; STN1, STN1, CST complex subunit; HTRA1, HtrA serine peptidase 1; TRIM22, tripartite motif containing 22; TRIM5, tripartite motif 
containing 5; HSD17B12, hydroxysteroid 17-beta dehydrogenase 12; ARHGAP42, Rho GTPase activating protein 42; C1S, complement C1s; NDUFA12, 
NADH:ubiquinone oxidoreductase subunit A12; PDS5B, PDS5 cohesin associated factor B; N4BP2L2, NEDD4 binding protein 2 like 2; MCF2L, MCF.2 cell line 
derived transforming sequence like; ARID4A, AT-rich interaction domain 4A; SERPINA2, serpin family A member 2 (gene/pseudogene); PLCG2, phospholipase 
C gamma 2; ANKRD13B, ankyrin repeat domain 13B; CORO6, coronin 6; COPRS, coordinator of PRMT5 and differentiation stimulator; KAT2A, lysine 
acetyltransferase 2A; DHX58, DExH-box helicase 58; ACAA2, acetyl-CoA acyltransferase 2; FCHO1, FCH domain only 1; MAP1S, microtubule associated 
protein 1S; ZHX3, zinc fingers and homeoboxes 3; ZNF335, zinc finger protein 335; PCIF1, PDX1 C-terminal inhibiting factor 1; ZNF831, zinc finger protein 
831; MAP3K7CL, MAP3K7 C-terminal like. 
 
8. Other Reports 
In addition to the foregoing studies of European 
populations, other studies evaluated CAD-associated 
loci in East Asian populations. Some of these studies are 
reviewed below. Several GWAS studies tried to identify 
novel loci involved in lipid metabolism in association 
with CAD; for example, Willer et al. (2008) confirmed 
strong associations between previously identified genes 
and reported new loci involved in lipid metabolism. 
Those confirmed in later studies included genes PCSK9 
(1p32.3), LDLR (19p13.2), and APOE (19q13.32) 
[49]. By 2013 157 loci were associated with lipid 
metabolism 157 [50]. Siewert et al. (2018) discovered 
six previously unreported loci associated with TG, LDL 
and total cholesterol and with CAD. These researchers 
performed a bivariate GWAS by combining data from a 
meta-analysis of CAD and the Global Lipid Genetics 
Consortium and detected variants causing increased 
levels of triglyceride, LDL and cholesterol associated 
with CAD [51]. Yamada et al. (2011) performed a 
GWAS study that identified locus BTN2A1 (6p22.1) 
associated with MI [52]. This gene caused hypertension 
in the Japanese population [53] and was probably 
associated with MI as a consequence. In the same year, 
Wang et al. (2011) discovered a C6orf105 (6p24.1) 
variant in a Chinese population. They reported SNP 
rs6903956 polymorphism that was associated with a 
reduced level C6orf105 mRNA and CAD susceptibility 
[54]. In a meta-analysis by combination of two GWAS 
Lu et al. (2012) discovered and later confirmed four loci 
in Chinese populations, including TTC32-WDR35 
(2p24.1), GUCY1A3 (4q32.1), C6orf10-BTNL2 
(6p21.32), and ATP2B1 (12q21.33) and confirmed 
SNP in the 9p21.3, PHACTR1, TCF21, C12orf51 loci 
that were identified previously in European populations 
[55]. Takeuchi et al. (2018) reported the association of 
three loci with CAD including BRAP and ALDH2 
(12q24) and MHC (6p21) and confirmation of 9p21.3 
in a Japanese population [56]. Lee et al. (2013) 
performed a GWAS in a Korean and Japanese 
population and loci which previously identified in 
European populations including 9p21.3, 1p13.3 and 
11q22.3 were confirmed. They found a strong 
association of an rs3782889 variant in gene MYL2 
(12q24.11) with CAD [57]. A recent study of the 
Japanese population identified twenty-six novel loci 
associated with early onset of CAD [58]. 
Although GWAS identified many loci or genes 
associated with CAD providing new insights on CAD 
pathophysiology, the specific clinical manifestations of 
those variants were not clear because very few of the 
variants were confirmed in other populations [59]. The 
best confirmed locus from all GWAS is 9p21.3. Different 
variants in this important locus were identified in GWAS 
confirmation many different ethnic groups emphasize 
the importance role of the region in CAD. 
Importance of Locus 9p21.3 in CAD 
The locus most often implicated in GWAS and in 
confirmation replication studies worldwide was 9p21.3. 
Clearly, this locus has an important role in CAD. The 
frequency of the risk alleles of 9p21.3 in different 
populations was variable, with the highest frequency of 
risk variants found in Europeans population (50%) and 
least in the African American population (24%) [60]. 
Surprisingly, some variants in this locus apparently 
protect the African American population from CAD 
[61]. The risk of CAD in homozygous mutant 
individuals is twofold greater than in heterozygous 
individuals [29, 62] indicating gene dosage effects of at 
least some SNPs in this locus on the disease. Gene 
dosage of 9p21.3 variants is also related to disease 
severity [63]. There is an association of particular 
9p21.3 variants with disease severity and mortality 
frequency [64] but quantitative factors in different 
populations produce confounding results. For example, 
the quantitative criteria for disease severity provided by 
quantitative coronary angiograms (QCA) based on 
vessel lumen diameter and numbers of lesions in 
coronary arteries in Caucasian individuals in a 
Lipoprotein and Coronary Atherosclerosis Study 
(LCAS) did not confirm any association of 9p21.3 
variation and CAD severity, the Gensini scoring system 
based on the rate of stenosis in coronary arteries 
confirmed the association of 9p21.3 variation and CAD 
severity in the Chinese population [65]. Also, two semi-
quantitative systems for scoring the severity and extent 
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of CAD confirmed the effect of 9p21.3 on the severity 
and progression of CAD [66]. 
In addition to possible effects of 9p21.3 on CAD 
severity, there is some evidence that shows an 
association of 9p21.3 variants with age at the time of 
disease onset [67]. Although there is an association 
between these variants and early onset MI [30] there 
does not seem to be an association with worsening 
clinical symptoms or mortality [68]. However, more 
serious clinical outcomes such as recurrent MI and 
mortality of patients with the acute coronary syndrome 
(ACS) has been associated with 9p21.3 [69]. There 
have been reports of some clinical signs and symptoms 
that lead to ACS, symptoms that are also dangerous 
manifestations of atherosclerosis in coronary arteries. 
Thus CAD patients are at the risk of ACS [70]. 
In summary, 9p21.3 variants are common among 
angiographic CAD cases and such variants can predict 
CAD prevalence independently of traditional risk 
factors among angiographical CAD patients [71]. 
The Structure of the 9p21.3 Locus in CAD 
The 9p21.3 sequence of about 55 Kb encompasses both 
coding and non-coding regions. There are four genes at 
the location, i.e., cyclin-dependent kinase inhibitors 
genes CDNK2A and CDNA2B, methylthioadenosine 
phosphorylase (MTAP) and ANRIL (antisense 
noncoding RNA in the INK4 locus). The first three are 
involved in proliferation of cells such as vessel smooth 
muscle cells (VSMCs) and inflammatory cells that are 
important in atherosclerosis [72-76]. The alternative 
splicing products of gene CDKN2A are p16ink4a and 
p14ARF and of gene CDKN2B is p15ink4b. This tumor 
suppressor region in 9p21 was identified by Kamb et al. 
as a multiple tumor suppressor (MTS) region [77]; the 
MTS1 region is identical to the p16 coding region or 
CDKN2A, which contains three exons and two 
transcripts from two different promoters. The p16ink4a 
and p14ARF proteins encoded by CDKN2A gene that has 
a different exon 1 sequence. p16ink4a is encoded by 
exon1α and p14ARF is encoded by a smaller transcript 
including exone1β [78, 79]. These inhibitors bind and 
inactivate CDK4/6 as well as stopping the signaling 
pathway that controls progression from cell division 
phase G1 to S and hence regulates cell proliferation [80, 
81] . These proteins are involved in tumor suppressor 
pathways, and contribute to essential cell processes such 
as the cell cycle, cell aging and apoptosis [82].  
MTAP encodes an enzyme involved in the methionine 
salvage pathway. Initially, the MTPA gene was identified 
to contain eight exons with a single transcript, but in 
2012 three additional exons and six additional 
transcripts (v1-v6) were discovered by Camacho-
Vanegas et al. [83]. Deficiencies of MTAP cause changes 
in the degree of genome methylation, reductions in 
methionine pathway metabolites and reduced CD4+ T-
cell counts [84]. MTAP is another gene involved in 
regulation of atherosclerosis and is known as a tumor 
suppressor gene [84, 85]. Generally, there is an 
association of this locus with susceptibility to 
atherosclerosis [86] accompanied by abnormal changes 
in intrinsic characteristics of arterial wall and 
susceptibility to vascular diseases [87, 88]. SNPs in this 
region are associated with various cardiovascular 
diseases such as CAD, carotid artery plaque, stroke, 
aneurysms, peripheral artery disease, and heart failure 
[89], and also other diseases including type 2 diabetes 
(T2D) [90], glaucoma [91, 92], several types of cancer 
[93], Alzheimer’s [94], endometriosis [95], and 
periodontitis [96]. 
Structural analysis of 9p21.3 includes the enhancer 
elements in the region [97, 98]. These enhancer 
elements physically interact with surrounding genes 
CDKN2A, CDKN2B, and MTAP and participate in 
long-range interaction with the interferon-α21 gene 
[98], but an effect of the 9p21.3 locus on CAD with 
modulation from type 1 interferon’s like interferon-α21 
has not been proved [99]. Risk alleles identified by 
GWAS can alter the activity of these enhancer elements; 
for example, SNP rs1333045 disrupts the Smad binding 
site with effects on cell proliferation by the TGF-β 
signaling pathway [97]; and rs10811656 and 
rs10757278 can disrupt the STAT1 binding site. 
STAT1 mediates cellular responses to interferon’s 
(INF). INFγ led to a 2-fold decrease in CDKN2B 
expression and a 4-fold increase in ANRIL expression. 
Thus, failure of STAT1 failed to bind to its binding site 
in this region there was an alteration in gene expression 
[98]. However, the relationship of 9p21.3 genotype and 
CAD is not clear since in another study expression of 
CDKN2A and CDKN2B was increased by the effects of 
INFγ treatment independently of risk genotype, 
therefore indicating that this locus plays a more 
complicated role in CAD [100]. The rs10811656 and 
rs4977757 variants disrupt a binding site of TEAD 
transcription factors, and affect p16 which is involved in 
regulation of gene expression and cell proliferation. This 
control process is likely to be damaged in individuals 
carrying risk alleles [101].  
Noncoding RNA is another mechanism for regulation of 
gene expression. The complex structure of 9p21.3 is due 
to noncoding regions. A transcripts of these regions is a 
long noncoding RNA named ANRIL (antisense 
noncoding RNA in the INK4 locus) [102]. This non-
coding RNA was first identified in a French family with 
melanoma-NST syndrome and harboring a germ-line 
deletion that included the ANRIL and INK4b-ARF-
INK4a cluster. The length of the ANRIL gene is 126.3 
Kb and it overlaps with the CDKN2B gene [103]. 
ANRIL has 20 exons and produces a long transcript of 
3,834 bp (DQ485353) and two shorter transcripts of 
2,659 bp and 688 bp (DQ485454 and EU741058, 
respectively) [97]. It has a complex regulatory role in 
different tissues and conditions due to its multiple 
transcripts. Variants in the region are associated with 
atherosclerosis [104, 105] and the linear/circular 
International Journal of Cardiovascular Practice  Omidi, et al. 
29 
structure of ANRIL affects the regulation of gene 
expression [106]. An animal model study indicated that 
homozygous deletions of ANRIL led to decreased 
Cdkn2a and Cdkn2b gene expression and an increased 
rate of mortality [75]. A study of association of 
polymorphisms in this locus with changes in gene 
expression indicated that ANRIL expression is altered to 
a greater extent than CDKN2A and CDKN2B; therefore, 
changes in ANRIL expression have important roles as 
causes of susceptibility to different diseases [107]. 
ANRIL, like other noncoding RNAs regulates gene 
expression by different mechanisms, including 
epigenetic regulation where it participates in chromatin 
remodeling and DNA methylation [108, 109]. 
Methylation of DNA in this region is associated with 
CAD [110]  
ANRIL as a non-coding RNA also plays a significant role 
in regulation of cis and trans genes [111]. A gene 
expression analysis study concluded that the expression 
of 46 genes in heart tissue was associated with common 
risk alleles of 9p21.3. The majority of these genes were 
involved in the transition of the cellular state from the 
G1 phase which is associated with the regulatory roles of 
the CDKN2A/B genes. Therefore, individuals carrying 
risk alleles are susceptible to increased cell proliferation 
and CAD risk. Transcription analysis showed risk 
variation at 9p21.3 is associated with ANRIL, 
CDKN2A/B, and C9orf53 (open reading frame) 
expression [111]. ABCA1 encodes a transporter protein 
that regulates the flow of cellular cholesterol from the 
cell membrane and HDL formation, hence this gene is 
associated with HDL level [113]. In another study of 
ANRIL, shRNA (short hairpin RNA) interference and 
knock-down of two transcripts demonstrated that the 
ADIPOR1, VAMP3 and C11ORF10 genes are regulated 
by ANRIL, meaning that ANRIL is involved in glucose 
and lipid metabolism regulated by these genes [114]. 
Furthermore, CARD8, another gene regulated by 
ANRIL expression is involved in ischemic stroke [115]. 
According to recent reports DUT, EIF1AY, CASP14, 
DHRS9, ABCA1, ADIPOR1, VAMP3, C11ORF10 and 
CARD8 are all regulated by ANRIL [116].  
PRC1 and PRC2 proteins participate in epigenetic 
regulation and histone remodeling [117]. The presence 
of Alu elements in the ANRIL region is necessary for 
trans regulation of ANRIL. These elements help ANRIL 
and the PRC1/2 complex to recognize their target genes 
[118]. A study of CAD patients in comparison with 
normal individuals showed the presence of four tandem 
duplications of about 50 kb in CAD patients [119].  
DISCUSSION 
9p21.3 and its variants represent a key candidate locus 
that is associated with CAD. In 2007, 9p21.3 was first 
recognized as a genomic  region associated with CAD; 
SNP rs1333049 and rs6475606 were identified as the 
strongest CAD-related variants [31]. Later, 
rs10757274, rs2383206 [29], rs2383207, rs10116277, 
rs1333040 and rs10757278 [30] were reported from 
two independent studies. These variants except for 
rs1333040 (excluded from the study because of 
erroneous application of the Hardy–Weinberg 
equilibrium in the control population) were confirmed 
in studies of European populations from the United 
Kingdom, Germany, Italy, and Sweden. All of these 
variants were confirmed with similar odds ratios ranging 
from 1.29 to 1.26 [120]. In another GWAS of the 
German population three variants, rs4977574, 
rs2891168 and rs1333042, were associated variants with 
CAD/MI [41]. Moreover, in separate GWAS, 
rs4977574 variant was implicated as a risk factor of MI 
[35] and CAD [36]. Variants rs3217992 [43] and 
rs1333042 were identified in another GWAS of 
European and South Asian populations [42]. 
The strongest indicator in most GWAS was the 
rs1333049 variant which was confirmed in other 
populations [32, 33]. An analysis of seven loci identified 
as risk loci for CAD provided clear evidence of a strong 
association of rs1333049 and CAD [33]. In another 
study of two large cohorts genotyping of three variants 
in three different loci established that rs1333049 was 
significantly associated with increased risk of CAD 
[121]. A meta-analysis of 9p21.3 variants showed there 
was a 29% increased risk of MI for individuals carrying 
each risk allele of a rs1333049 variant [122]. 
Various studies of Asian populations indicated a similar 
relationship of 9p21.3 variants with CAD; for example, 
rs9632884, rs10757274, rs1333042, rs1333049 were 
detected in a Chinese population [55], rs4977574 and 
rs1333049 in a Korean population [57], and rs1333049 
in a Japanese population [56]. The rs1333049 was the 
strongest signal in East Asian population being detected 
in Korean, Japanese, and Chinese as well as European 
populations. The present study also demonstrates the 
significant association of the rs6475606, rs4977574, 
rs29891168, rs1333042, rs1333048 and rs1333049 
variants with CAD [123]. 
The rs10811656 and rs10757278 variants are involved 
in disruption of transcription factors at the STAT1 
binding site [98]. These variants were more frequent in 
disease cases than in controls in a Polish population 
study [124]. rs10811656 and rs4977757 disrupt TEAD 
binding site [101] and the association of these risk 
alleles with CAD was confirmed in a Chinese population 
[125]. 
Association of three most frequently detected SNP, 
rs1333049, rs2383206 and rs10757278, in European 
populations was confirmed in a large meta-analysis of an 
East Asian population [126]. Among these variants, 
rs2383206 and rs10757278 displayed the closest 
association with CAD in an Indian population [127, 
128]. Investigation of CAD in a Saudi population 
identified four SNPs including rs564398, rs4977574, 
rs2891168, and rs1333042 associated with CAD/MI 
[129]. The first large case-control study (PROMIS) of a 
Pakistan population concluded that six (rs1333049, 
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rs10757274, rs4977574, rs2891168, rs1537372 and 
rs9632885) of eighty-nine investigated SNP in the 
9p21.3 locus were associated with MI [130]. In an 
analysis of an American Caucasian population with a 
familial history of CAD/MI, rs10757274, rs2383206, 
rs2383207, and rs10757278 were associated with the 
premature/familial form [131]. Moreover, these 
variants were confirmed in MI patients in German 
families with a high frequency of CAD/MI patients 
compared with families having no history of the 
condition [132].  
Studies of African American populations showed no 
association of 9p21.3 variants with CAD. For example, 
genotyping of rs10757274, rs2383206 and rs10757278 
variants showed no association variants in the African 
American population with CAD, but a haplotype 
analysis of African American patients found that they 
carried more risk alleles more than unaffected 
individuals [133]. Another surprising result was a study 
of an Iranian population where rs1333049 had no 
significant association with CAD whereas rs10757274 
was associated [134-137]. However, investigation of the 
rs10757274 and rs1333042 variants showed that the risk 
alleles of these SNP in a haplotype form did constitute a 
risk factor for CAD [137]. This demonstrated that some 
haplotype arrangements have protective effects against 
CAD, such as a GAAAA haplotype for five common 
variants, rs1333049, rs10757278, rs2383206, 
rs4977574 and rs10757274 [127]. 
The majority of SNP in the ANRIL gene were located in 
intronic regions, but recently two exonic variants were 
reported to be associated with MI. Sequencing of the 
promoter region and UTR upstream of ANRIL showed 
no variant significantly associated with MI [138]. Some 
other studies investigating the effects of 9p21.3 variants 
on expression and regulation of 9p21.3 genes indicated 
that rs1333049 altered the expression of CDKN2A/B 
and ANRIL. This alteration caused in proliferation of 
vascular smooth muscle cells (VSMC), and thereby an 
association with CAD [139, 140]. Moreover, 
rs10757278 reduced transcription of the p15, p16, p14 
and ANRIL genes leading to an increased risk of CAD 
[141]. 
CONCLUSION 
CAD is a complex multifactorial disease that causes 
plaque aggregation in coronary arteries leading to a 
decreased of blood supply to the heart muscles. 
Different studies showed a significant component of the 
variation in CAD was heritable. Mutations in genes 
involved in known pathways of CAD such as lipid 
metabolism including genes LDL receptor, ApoB-100, 
ARH and PCSK9 cause monogenic forms of CAD. The 
locus most frequently implicated in GWAS was 9p21.3. 
Different variants in this locus associated with CAD 
were discovered and confirmed in many ethnic 
populations. Clearly, variation in 9p21.3 is strongly 
associated CAD and has a significant role in 
atherosclerosis. It seems that variants confirmed in 
different populations, including rs1333049, 
rs10757278, rs10757274, rs2383206, rs6475606, 
rs2383207, rs10116277, rs1333040, rs4977574, 
rs2891168, rs1333042, rs1333048 and 1333045, can be 
used in etiology and research on cardiovascular disease. 
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